Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Operating Leases (2020 - 2025)

Tango Therapeutics has reported Operating Leases over the past 6 years, most recently at $30.8 million for Q4 2025.

  • Quarterly results put Operating Leases at $30.8 million for Q4 2025, down 9.42% from a year ago — trailing twelve months through Dec 2025 was $30.8 million (down 9.42% YoY), and the annual figure for FY2025 was $30.8 million, down 9.42%.
  • Operating Leases for Q4 2025 was $30.8 million at Tango Therapeutics, down from $31.7 million in the prior quarter.
  • Over the last five years, Operating Leases for TNGX hit a ceiling of $39.9 million in Q3 2022 and a floor of $6.1 million in Q3 2021.
  • Median Operating Leases over the past 5 years was $35.5 million (2024), compared with a mean of $33.7 million.
  • Biggest five-year swings in Operating Leases: soared 556.05% in 2022 and later decreased 9.42% in 2025.
  • Tango Therapeutics' Operating Leases stood at $6.1 million in 2021, then soared by 546.43% to $39.4 million in 2022, then decreased by 6.41% to $36.8 million in 2023, then decreased by 7.6% to $34.0 million in 2024, then dropped by 9.42% to $30.8 million in 2025.
  • The last three reported values for Operating Leases were $30.8 million (Q4 2025), $31.7 million (Q3 2025), and $32.5 million (Q2 2025) per Business Quant data.